{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T11:12:12Z","timestamp":1768648332737,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"37","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.vaccine.2020.07.009","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T17:34:22Z","timestamp":1595439262000},"page":"5914-5922","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Safety of meningococcal B vaccine (4CMenB) in adolescents in Australia"],"prefix":"10.1016","volume":"38","author":[{"given":"H.S.","family":"Marshall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.P.","family":"Koehler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"A'Houre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1851-5080","authenticated-orcid":false,"given":"N.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Pratt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.R.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4675-0232","authenticated-orcid":false,"given":"K.","family":"Macartney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.07.009_b0005","unstructured":"Australian Government Department of Health. Meningococcal W Disease. Canberra; 2018 [updated 26 September 2018; cited 11 October 2018]. Available from: http:\/\/www.health.gov.au\/internet\/main\/publishing.nsf\/Content\/ohp-meningococcal-W.htm."},{"issue":"4","key":"10.1016\/j.vaccine.2020.07.009_b0010","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14760584.2017.1258308","article-title":"The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection","volume":"16","author":"Borrow","year":"2017","journal-title":"Expert Rev Vacc"},{"issue":"7","key":"10.1016\/j.vaccine.2020.07.009_b0015","doi-asserted-by":"crossref","first-page":"e020988","DOI":"10.1136\/bmjopen-2017-020988","article-title":"B Part of It protocol: a cluster randomised controlled trial to assess the impact of 4CMenB vaccine on pharyngeal carriage of Neisseria meningitidis in adolescents","volume":"8","author":"Marshall","year":"2018","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.vaccine.2020.07.009_b0020","doi-asserted-by":"crossref","first-page":"E156","DOI":"10.33321\/cdi.2013.37.22","article-title":"Adolescent school-based vaccination in Australia","volume":"37","author":"Ward","year":"2013","journal-title":"Commun Dis Intell Q Rep"},{"issue":"10061","key":"10.1016\/j.vaccine.2020.07.009_b0025","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1016\/S0140-6736(16)31921-3","article-title":"Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study","volume":"388","author":"Parikh","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2020.07.009_b0030","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S2352-4642(18)30103-2","article-title":"Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study","volume":"2","author":"Bryan","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.vaccine.2020.07.009_b0035","unstructured":"De Serres G, Gari\u00e9py MC, Billard MN, Rouleau I. Initial dose of a multicomponent serogroup B meningococcal vaccine in the Saguenay-Lac-Saint-Jean Region, Qu\u00e9bec, Canada: An interim safety surveillance report: Institut national de sant\u00e9 publique du Qu\u00e9bec, Direction des risques biologiques et de la sant\u00e9 au travail; 2014."},{"issue":"52","key":"10.1016\/j.vaccine.2020.07.009_b0040","first-page":"8039","article-title":"Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec","volume":"36","author":"De Serres","year":"2018","journal-title":"Canada Vacc"},{"issue":"5","key":"10.1016\/j.vaccine.2020.07.009_b0045","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/IPC.0000000000000197","article-title":"Addressing the challenges of serogroup B meningococcal disease outbreaks on campuses","volume":"22","author":"Schaffner","year":"2014","journal-title":"Infect Dis Clin Pract"},{"issue":"34","key":"10.1016\/j.vaccine.2020.07.009_b0050","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1016\/j.vaccine.2016.06.025","article-title":"Rapid surveillance for health events following a mass meningococcal B vaccine program in a university setting: A Canadian Immunization Research Network study","volume":"34","author":"Langley","year":"2016","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2020.07.009_b0055","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/14760584.2018.1432360","article-title":"Protecting UK adolescents and adults against meningococcal serogroup B disease","volume":"17","author":"Vyse","year":"2018","journal-title":"Expert Rev Vacc"},{"issue":"3","key":"10.1016\/j.vaccine.2020.07.009_b0060","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1128\/CVI.00304-10","volume":"18","author":"Kimura","year":"2011","journal-title":"Clin Vacc Immunol: CVI"},{"issue":"9816","key":"10.1016\/j.vaccine.2020.07.009_b0065","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.07.009_b0070","unstructured":"Australian Bureau of Statistics. Table 42b number of full-time and part-time students, 2006-2017 Australian Bureau of Statistics; 2018 [updated 2 February 2018; cited 5 December 2018]. Available from: http:\/\/www.abs.gov.au\/AUSSTATS\/abs@.nsf\/DetailsPage\/4221.02017?OpenDocument."},{"key":"10.1016\/j.vaccine.2020.07.009_b0075","unstructured":"Australian Technical Advisory Group on Immunisation (ATAGI). The Australian Immunisation Handbook. Canberra: Australian Government Department of Health; 2018 [updated 01 November 2018; cited 30 January 2019]. Available from: immunisationhandbook.health.gov.au."},{"key":"10.1016\/j.vaccine.2020.07.009_b0080","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.vaccine.2008.11.036","article-title":"Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies","volume":"27","author":"Bonhoeffer","year":"2009","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2020.07.009_b0085","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1080\/21645515.2016.1192737","article-title":"AEFI-CAN network. Adverse events following HPV immunization in Australia: Establishment of a clinical network","volume":"12","author":"Crawford","year":"2016","journal-title":"Hum Vacc Immunother"},{"issue":"4","key":"10.1016\/j.vaccine.2020.07.009_b0090","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4103\/2229-3485.120173","article-title":"Causality assessment: A brief insight into practices in pharmaceutical industry","volume":"4","author":"Naidu","year":"2013","journal-title":"Perspect Clin Res"},{"key":"10.1016\/j.vaccine.2020.07.009_b0095","doi-asserted-by":"crossref","unstructured":"Marshall HS, McMillan M, Koehler AP, Lawrence A, Sullivan TR, MacLennan JM, et al. Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. 2020;382(4):318\u201327.","DOI":"10.1056\/NEJMoa1900236"},{"issue":"14","key":"10.1016\/j.vaccine.2020.07.009_b0100","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1016\/j.vaccine.2020.02.046","article-title":"Immunization stress-related response - Redefining immunization anxiety-related reaction as an adverse event following immunization","volume":"38","author":"Gold","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.07.009_b0105","article-title":"Surveillance of adverse events following immunisation in Australia: annual report, 2018","volume":"44","author":"Dey","year":"2018","journal-title":"Commun Dis Intell"},{"issue":"4","key":"10.1016\/j.vaccine.2020.07.009_b0110","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1753-6405.2009.00409.x","article-title":"Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia","volume":"33","author":"Watson","year":"2009","journal-title":"Aust N Z J Public Health"},{"key":"10.1016\/j.vaccine.2020.07.009_b0115","doi-asserted-by":"crossref","DOI":"10.33321\/cdi.2018.42.9","article-title":"Surveillance of adverse events following immunisation in Australia annual report, 2016","volume":"42","author":"Dey","year":"2018","journal-title":"Commun Dis Intell"},{"issue":"12","key":"10.1016\/j.vaccine.2020.07.009_b0120","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.4161\/hv.34369","article-title":"Consumer reporting of adverse events following immunization","volume":"10","author":"Clothier","year":"2014","journal-title":"Hum Vacc Immunother"},{"issue":"3","key":"10.1016\/j.vaccine.2020.07.009_b0125","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-3707","article-title":"Risk of recurrence of adverse events following immunization: a systematic review","volume":"140","author":"Zafack","year":"2017","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.vaccine.2020.07.009_b0130","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/INF.0000000000002162","article-title":"Rate of recurrence of adverse events following immunization: results of 19 years of surveillance in Quebec, Canada","volume":"38","author":"Zafack","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.07.009_b0135","unstructured":"mondiale de la Sant\u00e9 O, World Health Organization. Global advisory committee on vaccine safety, 5\u20136 December 2018. Week Epidemiol Rec 2019;94(4):45-52."},{"issue":"8","key":"10.1016\/j.vaccine.2020.07.009_b0140","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1080\/21645515.2018.1460293","article-title":"Potential immediate hypersensitivity reactions following immunization in preschool aged children in Victoria, Australia","volume":"14","author":"Baxter","year":"2018","journal-title":"Hum Vacc Immunother"},{"issue":"5","key":"10.1016\/j.vaccine.2020.07.009_b0145","doi-asserted-by":"crossref","first-page":"261","DOI":"10.5694\/j.1326-5377.2008.tb02018.x","article-title":"Mass psychogenic response to human papillomavirus vaccination","volume":"189","author":"Buttery","year":"2008","journal-title":"Med J Aust"},{"issue":"19","key":"10.1016\/j.vaccine.2020.07.009_b0150","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1016\/j.vaccine.2017.03.035","article-title":"Assessment of sex-specific differences in adverse events following immunization reporting in Ontario, 2012\u201315","volume":"35","author":"Harris","year":"2017","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20309099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20309099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:45:18Z","timestamp":1759401918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20309099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":30,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0264410X20309099"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.07.009","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of meningococcal B vaccine (4CMenB) in adolescents in Australia","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}